Simufilam: Clinical Trials

4 trials of Simufilam, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Terminated 1

Follow Simufilam: new trials by email Literature Review of Simufilam trials Research Report on Simufilam

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
simufilam - Alzheimer's Disease
Phase 2TerminatedCassava Sciences, Inc.902022-05-122025-08-15
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
Simufilam 100 mg oral tablet, Placebo - Alzheimer Disease
Phase 2CompletedCassava Sciences, Inc.2202020-03-242025-04-22
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Placebo oral tablet, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet - Alzheimer Disease
Phase 2CompletedCassava Sciences, Inc.642019-09-092021-09-29
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
PTI-125, 100 mg tablets - Alzheimer Disease
Phase 2CompletedPain Therapeutics132019-03-072021-07-07

Conditions studied

Alzheimer Disease (4)

Sponsors

Cassava Sciences, Inc. (3)  ·  Pain Therapeutics (1)

Countries

United States (4)  ·  Canada (2)

Top investigators

Lindsay Burns, PhD (3)  ·  Chris Cook, JD (1)

Results publications

PMID 32920628, PMID 33188449, PMID 36934371

NIH funding

R44AG060878 (2), R44AG065152 (1)